Support Dr Leanne Robinson and her PNG partners' crucial work to control and eliminate lymphatic filariasis.
“We haven’t had a National Overdose Strategy since 2001 in Australia and we need one now.” - Professor Paul Dietze, Program Director, Behaviours and Health Risks, Burnet Institute.
That was one of the key messages resonating from the CREIDU & MARC symposium, ‘Preventing and responding to opioid overdose in Victoria: Developments and opportunities’ held in Melbourne this week.
“There is currently no consistent legislation, no national coordination, no distribution targets, no intranasal naloxone, and no standard universal access through health services of the overdose reversal drug, naloxone,” Professor Dietze told the packed audience, including many who had travelled from regional Victorian centres and country towns.
Naloxone hydrochloride (trade name Narcan®) and often referred to as take-home naloxone (THN), has had an immediate impact on reversing many overdoses since being approved for wider community use.
Image: Sione Crawford, Executive Officer, Harm Reduction Victoria
Naloxone works by blocking opioid drugs, such as heroin and methadone, from attaching to opioid receptors in the brain.
It can be injected intravenously (into a vein) or intramuscularly (into a muscle) by medical professionals such as paramedics.
It can also be administered by family and friends of people who use opiates, and be purchased over the counter at pharmacies or via prescription as an ampoule or pre-filled, five-dose syringe.
But what dose of naloxone should be used to reverse an overdose? Currently, according to Professor Dietze there is no universal direction and certainly no national standard in Australia.
“The World Health Organization recommends 400mcg, Ambulance Victoria uses 1.6mg despite using 400mcg ampules, and Ambulance NSW says 400mcg is best,” Professor Dietze said.
Image: Sarah Hiley, Team Leader at the North Richmond Medically Supervised Injecting Room (MSIR)
Some of the key messages from the Symposium included:
Professor Dietze said progress is being made in the uptake and awareness of the overdose-reversing drug, with more than 3000 take-home naloxone kits being delivered.
“There is a lot of momentum at the moment with the MSIR having twice as many visits as the Sydney equivalent in its first two months of opening,” he said.
“We know this is a successful model that could lead to the rollout of intervention in other states of Australia.”
For more information in relation to this news article, please contact:
Program Director, Behaviours and Health Risks